Looking ahead, the United States is expected to retain its dominant position within the toxicology testing market, although as with many areas of the pharmaceutical industry, the greatest levels of growth are expected to be seen in Asia Pacific.
The meeting was kicked off by John Wise, Executive Director at Pistoia Alliance, who shared a delightful, anecdote-filled review of the current pharma R&D business landscape. In his talk, he gave detailed evidence of how different pharma companies were comparing the amount they spend to bring each new drug to market. He highlighted just ‘being big’ was not enough, and explained how a company’s approach to innovation also plays a role in the drug discovery process.
Regenerative medicine is one of the fastest growing industries with huge market potential, it handles the treatment of chronic diseases which remained incurable previously. Cell therapy using live cells is widely used to replace damaged cells, deliver therapies to target tissues/organs, stimulate self-healing, and various other applications in regenerative medicine.
The brawl up to the US election has been almost impossible to miss. Amidst watching Trump and Hillary lock-horns, Pharma-IQ examines one of the most important battlegrounds discussed - the future of US healthcare.
Pharma power play hinges mostly on the initial R&D race to market dominance. Research innovation and investment has enticing potential. The Pharmaceutical industry pipeline was noted to have seen a 5% year on year increase in the first quarter of 2016 1 . Just under 70% of that pipeline is covered by the therapy areas of oncology, infectious diseases and central nervous system disorders. The same report noted that the price to bring a single novel drug to market rested at around $2.6 billion in 2015.
n the pharmaceutical and fine chemical industries, reactions are often exothermic. Though they have inherent safety hazards at small scale, these risks can be alleivated by operating in semi-batch mode with solid or reagent dosing. While monitoring batch temperature can be used to control thermal risk, upon scale-up to larger jacketed glass reactors, heat removal becomes limited due to decreasing surface area to volume ratios, and this introduces new risks.
To meet the growing demand, medical manufacturing is adapting disruptive technologies that are reshaping manufacturing as a whole and displacing established practices. Here’s a look at some of the disruptive trends that are transforming medical manufacturing.
Following a quarter that featured reports stating that Novartis had dramatically redistributed its cell and gene therapy unit 1 and saw the public focus turn once again to drug price hikes, Pharma IQ brings you the pharma, biotech and life sciences news highlights for Q3 of 2016.
Currently, two trends are in focus for the clinical trial supply chain: patient centricity and the usage of the Internet of Things (IoT) in clinical trials. Both components are driven by the need to shorten clinical development timelines, reduce costs and improve data quality. The clinical supply chain can contribute significantly to these objectives.
Earlier this month, Industry members gathered to tackle challenges and contribute to the discussion surrounding cell and gene therapies and their manufacture.